SHS Gesellschaft für Beteiligungsmanagement has announced the first closing of its fund SHS IV. SHS focuses its investment on high-growth medical technology companies in Germany, Austria and Switzerland with marketable products and technologies.
The Tübingen based SHS Gesellschaft für Beteiligungsmanagement has announced the successful first closing of its fund SHS IV today. By December 2013, SHS secured 56 million euro of growth capital for its fourth fund. SHS focuses its investment on high-growth medical technology companies in Germany, Austria and Switzerland with marketable products and technologies. The target volume for SHS IV is 100 million euro, which is twice the amount of the previous SHS fund SHS III.
With its fourth fund, SHS is continuing an investment strategy, with which the previous funds achieved above average yields even in difficult market phases. After all, young medical companies in the particularly innovative DACH region are targeting a global high-growth market and attract a high level of interest among strategic buyers. Global trends including the aging population in the industrial world and increasing prosperity in emerging economies promise consistent strong growth in the years to come as well. Germany, Austria and Switzerland provide an outstanding investment environment, which is distinguished by attractive investment options and calculable regulatory conditions. SHS, which has been active in the investment business for 20 years, is among the first in the growth capital providers segment to be registered according to the AIFM directive, which stipulates particularly high standards regarding the company’s investment expertise, reliability and systems.
“We are very pleased with our fourth fund’s first closing. The fact that we have already secured 56 million euro in the first closing for investment in innovative medical technology companies is a show of faith among the investors in the attractiveness of medical technology and stands for our team’s experience as well as the success of the previous funds. We have been working closely with many of these investors for many years and are confident that we will also provide attractive opportunities to our investors with SHS IV”, explains SHS Managing Partner Hubertus Leonhardt.
Almost 50 percent of the investors in SHS IV have already invested in one of the three previous SHS funds. The SHS team has also gained new investors including pension plans, pension funds and family offices.
“With the SHS IV, we will be investing in promising medical technology companies to accelerate their establishment on the market. In doing so, we will be focusing on innovations that advance patient treatment or help provide more cost-effective access to high-quality medicine. We plan on investing in two to four medical technology companies each year using growth capital from the SHS IV fund”, explains SHS partner Dr. André Zimmermann.
The SHS team’s years of experience and its proven expertise when it comes to medical technology and life sciences are among the decisive success factors of the growth investor from Tübingen. SHS invests in innovative companies with marketable products and high growth potential. Examples from previous funds include phenox, a product innovator in interventional neuroradiology and numares, which develops and markets diagnostics solutions based on nuclear magnetic resonance (NMR) spectroscopy.
About SHS Gesellschaft für Beteiligungsmanagement mbH:
The principle partners of SHS, which has been active in the investment business for 20 years, are former McKinsey consultants Bernhard Schirmers and Reinhilde Spatscheck along with Hubertus Leonhardt, former Corporate Finance Project Leader at Arthur Andersen. Investors have provided around 56 million euro for the current SHS IV fund. SHS is among the first in the growth capital providers segment to be registered according to the AIFM directive, which stipulates particularly high standards regarding the investment company’s expertise, reliability and systems. Investors in SHS IV include the European Investment Fund, which also bolstered the previous fund as strategic anchor investor with capital from the ERP-EIF facility, professional pension plans, pension funds and funds of funds as well as entrepreneurs, family offices and the SHS management team itself. The fund will remain open to other institutional investors and family offices until completion of the final closing in 2014.